0 15 Transactivation Transactivation NNP 16 18 of of IN 19 22 the the DT 23 28 human human JJ 29 45 immunodeficiency immunodeficiency NN 46 51 virus virus NN 52 60 promoter promoter NN 61 63 by by IN 64 69 human human JJ 70 81 herpesvirus herpesvirus NN 82 83 6 6 CD 84 85 ( ( ( 85 90 HHV-6 hhv-6 NN 90 91 ) ) ) 92 99 strains strain NNS 100 102 GS gs NN 103 106 and and CC 107 111 Z-29 z-29 NN 112 114 in in IN 115 122 primary primary JJ 123 128 human human JJ 129 130 T t NN 131 142 lymphocytes lymphocyte NNS 143 146 and and CC 147 161 identification identification NN 162 164 of of IN 165 180 transactivating transactivate VBG 181 190 HHV-6(GS) hhv-6(gs) NN 191 195 gene gene NN 196 205 fragments fragment NNS 205 206 . . . 208 213 Human human JJ 214 225 herpesvirus herpesvirus NN 226 227 6 6 CD 228 229 ( ( ( 229 234 HHV-6 hhv-6 NN 234 235 ) ) ) 236 239 can can MD 240 248 activate activate VB 249 252 the the DT 253 258 human human JJ 259 275 immunodeficiency immunodeficiency NN 276 281 virus virus NN 282 283 ( ( ( 283 286 HIV HIV NNP 286 287 ) ) ) 288 296 promoter promoter NN 297 300 and and CC 301 311 accelerate accelerate VB 312 322 cytopathic cytopathic JJ 323 330 effects effect NNS 331 333 in in IN 334 346 HIV-infected hiv-infected JJ 347 352 human human JJ 353 354 T t NN 355 360 cells cell NNS 360 361 . . . 362 366 This this DT 367 372 study study NN 373 381 examines examine VBZ 382 385 the the DT 386 393 regions region NNS 394 396 of of IN 397 400 the the DT 401 404 HIV HIV NNP 405 413 promoter promoter NN 414 422 required require VBN 423 426 for for IN 427 432 HHV-6 HHV-6 NNP 433 448 transactivation transactivation NN 449 451 in in IN 452 453 a a DT 454 467 heterogeneous heterogeneous JJ 468 478 population population NN 479 481 of of IN 482 489 primary primary JJ 490 495 human human JJ 496 497 T t NN 498 509 lymphocytes lymphocyte NNS 510 514 with with IN 515 517 or or CC 518 525 without without IN 526 535 antigenic antigenic JJ 536 547 stimulation stimulation NN 547 548 . . . 549 552 Two two CD 553 562 different different JJ 563 570 strains strain NNS 571 573 of of IN 574 579 HHV-6 HHV-6 NNP 579 580 , , , 581 583 GS GS NNP 584 587 and and CC 588 591 Z29 Z29 NNP 591 592 , , , 593 607 transactivated transactivate VBD 608 611 the the DT 612 615 HIV HIV NNP 616 624 promoter promoter NN 624 625 . . . 626 629 The the DT 630 632 GS gs NN 633 639 strain strain NN 640 654 transactivated transactivate VBD 655 658 the the DT 659 667 promoter promoter NN 668 670 in in IN 671 675 both both CC 676 686 stimulated stimulate VBN 687 690 and and CC 691 698 resting rest VBG 699 700 T t NN 701 706 cells cell NNS 706 707 , , , 708 713 while while IN 714 717 the the DT 718 721 Z29 z29 NN 722 728 strain strain NN 729 738 increased increase VBD 739 742 HIV HIV NNP 743 751 promoter promoter NN 752 760 activity activity NN 761 765 only only RB 766 768 in in IN 769 779 stimulated stimulate VBN 780 781 T t NN 782 787 cells cell NNS 787 788 . . . 789 794 Three three CD 795 798 DNA DNA NNP 799 805 clones clone NNS 806 816 containing contain VBG 817 826 HHV-6(GS) hhv-6(gs) NN 827 834 genomic genomic JJ 835 844 fragments fragment NNS 845 859 transactivated transactivate VBD 860 863 the the DT 864 867 HIV HIV NNP 868 876 promoter promoter NN 877 879 in in IN 880 893 cotransfected cotransfecte VBN 894 895 T t NN 896 901 cells cell NNS 901 902 . . . 903 904 A a DT 905 912 21.4-kb 21.4-kb JJ 913 916 DNA dna NN 917 922 clone clone NN 922 923 , , , 924 930 pZVB70 pzvb70 NN 930 931 , , , 932 938 showed show VBD 939 942 the the DT 943 950 highest high JJS 951 966 transactivating transactivating NN 967 974 ability ability NN 974 975 , , , 976 981 while while IN 982 985 two two CD 986 991 other other JJ 992 995 DNA dna NN 996 1005 fragments fragment NNS 1005 1006 , , , 1007 1013 pZVB10 pzvb10 NN 1014 1015 ( ( ( 1015 1018 6.2 6.2 CD 1019 1021 kb kb NN 1021 1022 ) ) ) 1023 1026 and and CC 1027 1033 pZVH14 pzvh14 NN 1034 1035 ( ( ( 1035 1038 8.7 8.7 CD 1039 1041 kb kb NN 1041 1042 ) ) ) 1042 1043 , , , 1044 1050 showed show VBD 1051 1056 lower low JJR 1057 1065 activity activity NN 1065 1066 . . . 1067 1070 One one CD 1071 1073 of of IN 1074 1079 these these DT 1080 1086 clones clone NNS 1086 1087 , , , 1088 1094 pZVH14 pzvh14 NN 1094 1095 , , , 1096 1105 activated activate VBD 1106 1109 the the DT 1110 1113 HIV HIV NNP 1114 1122 promoter promoter NN 1123 1132 construct construct NN 1133 1143 containing contain VBG 1144 1145 a a DT 1146 1154 mutation mutation NN 1155 1157 in in IN 1158 1161 the the DT 1162 1164 NF NF NNP 1165 1170 kappa kappa NN 1171 1172 B B NNP 1173 1177 site site NN 1177 1178 . . . 1179 1186 However however RB 1186 1187 , , , 1188 1192 this this DT 1193 1200 mutated mutate VBN 1201 1203 NF NF NNP 1204 1209 kappa kappa NN 1210 1211 B B NNP 1212 1220 promoter promoter NN 1221 1224 was be VBD 1225 1228 not not RB 1229 1243 transactivated transactivate VBN 1244 1250 during during IN 1251 1260 HHV-6(GS) hhv-6(gs) NN 1261 1270 infection infection NN 1271 1273 or or CC 1274 1279 after after IN 1280 1294 cotransfection cotransfection NN 1295 1299 with with IN 1300 1306 pZVB70 pzvb70 NN 1307 1309 or or CC 1310 1316 pZVB10 pzvb10 NN 1316 1317 . . . 1318 1323 These these DT 1324 1328 data datum NNS 1329 1337 indicate indicate VBP 1338 1342 that that IN 1343 1346 the the DT 1347 1349 NF NF NNP 1350 1355 kappa kappa NN 1356 1357 B B NNP 1358 1363 sites site NNS 1364 1366 of of IN 1367 1370 the the DT 1371 1374 HIV HIV NNP 1375 1383 promoter promoter NN 1384 1387 are be VBP 1388 1397 essential essential JJ 1398 1401 for for IN 1402 1405 its its PRP$ 1406 1421 transactivation transactivation NN 1422 1428 during during IN 1429 1438 HHV-6(GS) hhv-6(gs) NN 1439 1448 infection infection NN 1448 1449 . . . 1450 1452 By by IN 1453 1463 increasing increase VBG 1464 1467 HIV HIV NNP 1468 1476 promoter promoter NN 1477 1485 activity activity NN 1486 1488 in in IN 1489 1496 primary primary JJ 1497 1498 T t NN 1499 1510 lymphocytes lymphocyte NNS 1510 1511 , , , 1512 1517 HHV-6 HHV-6 NNP 1518 1521 may may MD 1522 1534 consequently consequently RB 1535 1543 increase increase VB 1544 1547 HIV HIV NNP 1548 1559 replication replication NN 1559 1560 , , , 1561 1568 leading lead VBG 1569 1571 to to TO 1572 1574 an an DT 1575 1583 increase increase NN 1584 1586 in in IN 1587 1590 the the DT 1591 1601 cytopathic cytopathic JJ 1602 1608 effect effect NN 1609 1611 on on IN 1612 1622 coinfected coinfecte VBN 1623 1628 human human JJ 1629 1630 T t NN 1631 1636 cells cell NNS 1636 1637 . . .